TD Cowen Issues Positive Forecast for Twist Bioscience (NASDAQ:TWST) Stock Price

Twist Bioscience (NASDAQ:TWST) had its price target lifted by TD Cowen from $32.00 to $43.00 in a report published on Thursday morning,Benzinga reports. TD Cowen currently has a buy rating on the stock.

A number of other equities analysts have also weighed in on TWST. Cowen reiterated a “buy” rating on shares of Twist Bioscience in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Stephens initiated coverage on Twist Bioscience in a report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price objective for the company. Barclays boosted their target price on Twist Bioscience from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Finally, Evercore ISI reaffirmed an “outperform” rating and set a $42.00 price target on shares of Twist Bioscience in a research note on Monday. Nine research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.67.

Twist Bioscience Stock Down 5.0%

NASDAQ:TWST opened at $34.74 on Thursday. Twist Bioscience has a 1 year low of $23.30 and a 1 year high of $55.33. The company has a current ratio of 3.64, a quick ratio of 3.33 and a debt-to-equity ratio of 0.03. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -26.52 and a beta of 2.19. The stock has a 50-day moving average price of $31.44 and a two-hundred day moving average price of $31.17.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. The business had revenue of $99.01 million for the quarter, compared to the consensus estimate of $97.40 million. As a group, equities analysts expect that Twist Bioscience will post -2.12 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Paula Green sold 6,920 shares of Twist Bioscience stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $31.44, for a total value of $217,564.80. Following the completion of the transaction, the senior vice president owned 143,271 shares of the company’s stock, valued at $4,504,440.24. This trade represents a 4.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Emily M. Leproust sold 31,379 shares of the company’s stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $986,555.76. Following the completion of the sale, the chief executive officer directly owned 738,809 shares in the company, valued at approximately $23,228,154.96. The trade was a 4.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 60,699 shares of company stock valued at $1,919,823 in the last ninety days. 3.01% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently bought and sold shares of TWST. Quarry LP acquired a new position in shares of Twist Bioscience during the 3rd quarter worth approximately $28,000. Smartleaf Asset Management LLC increased its holdings in shares of Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after purchasing an additional 442 shares during the last quarter. National Bank of Canada FI bought a new position in shares of Twist Bioscience in the third quarter valued at about $46,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after purchasing an additional 302 shares during the period. Finally, Geneos Wealth Management Inc. acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth about $97,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.